Intermediate disease
Dry Age-Related Macular Degeneration
Until recently the honest answer to the dry AMD question was supplements and observation. Recently published trials changed that: 51% of treated patients gained at least one line over two years, with measurable drusen reduction - and, for the first time, no geographic atrophy forming beneath resolving drusen.
What helps measure it
- Baseline OCT with drusen assessment
- Best corrected acuity documented against the trial range (20/32 to 20/70)
- Age and candidacy review against the published trial criteria (50 or older, no central geographic atrophy)
Clinical relevance: Photobiomodulation is considered in relation to mitochondrial support, oxidative stress and inflammatory signaling, with OCT, acuity and drusen change used to evaluate response over time.
Managed conservatively
Geographic Atrophy
Lesions can appear to grow early in treatment, but the expansion rate slows markedly against untreated progression. The target is the inflammation at the border between atrophied and healthy tissue, where complement cascade activity drives lesion growth.
What helps measure it
- OCT with geographic atrophy lesion mapping
- Energy-exposure planning per eye, including patching schedules when one eye carries more risk
- Dermatology and photosensitivity review
Clinical relevance: The clinical focus is the metabolically active border between atrophied and healthy tissue, with serial imaging used to distinguish tissue response from untreated progression.
Restaged at every entry point
Evaporative Dry Eye
Evaporative, aqueous-deficient and mixed presentations do not respond to the same sequence. Restaging first is what makes device outcomes reproducible - and photobiomodulation now covers the presentations IPL physically cannot reach.
What helps measure it
- Symptom questionnaire and tear film assessment
- Meibography, or meibomian gland imaging, with dropout and expressibility grading
- Lid margin and Demodex evaluation
Clinical relevance: Therapy is selected by the vascular, inflammatory and glandular findings. Photobiomodulation can reach upper-lid and lash-line tissue that a limited IPL treatment field cannot.
Obstructive and inflammatory subtypes
Meibomian Gland Dysfunction
Gland structure, not symptom score, determines how much recovery is realistic. Set that expectation before the first treatment.
What helps measure it
- Meibography, or meibomian gland imaging, with dropout grading
- Expression quality by gland region
- Blink completeness assessment
Clinical relevance: Gland structure, inflammatory load and meibum quality guide how IPL, RF and home therapy are considered together.
Chronic, relapsing
Ocular Rosacea and Lid Margin Disease
Lid margin vasculature is the target. Patients need a maintenance plan, not a one-time course.
What helps measure it
- Lid margin telangiectasia grading
- Skin type and photosensitivity screening
- Dermatology co-management review
Clinical relevance: IPL with defined maintenance intervals and documented consent.
Beyond the traditional critical period
Amblyopia
A 2012 German study reported improvement in 90% of treated amblyopic eyes, with half gaining three or more lines - well past the classic critical period. Dr. Brothers has replicated the pattern, including a 17-year-old moving from 20/100 to 20/40 and then 20/25 across treatment cycles.
What helps measure it
- Best corrected acuity in each eye, tracked visit to visit
- Refraction and anisometropia review - anisometropia has resolved in several treated hyperopes
- Multifocal ERG where objective confirmation of retinal function change is wanted
Clinical relevance: Acuity and, where appropriate, multifocal ERG help assess whether light exposure is associated with functional retinal change beyond subjective perception.
Progressive myopia
Myopia Control
Repeated red light therapy outperformed diluted atropine and orthokeratology on axial-length change in comparative trials - making it one of the more compelling options in the myopia control conversation.
What helps measure it
- Axial length and cycloplegic refraction baseline
- Prescription stability review at six weeks of treatment
- Home device safety briefing with timer verification
Clinical relevance: Axial length and refraction are followed to evaluate the response to red light therapy, with device safety and prescription stability kept central to clinical decisions.
Bring your own cases
Training works through the cases in front of you, from tissue mechanism and patient selection to the imaging and functional tests that document change.